Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

14,15-EET may help reduce poststroke pain by affecting certain brain proteins.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Setipiprant did not significantly improve hair growth in men with hair loss.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

AH-001 could be a safer and more effective treatment for hair loss.

Adiantum capillus extract reduces pain and swelling in animals.

Dexmedetomidine-loaded microneedles effectively reduce pain without sedation.

The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

The drug combination was safe and showed promise in treating advanced tumors.